Global

Portobello Capital has closed its fifth flagship buyout fund on €710m, beating its €600m target after less than 18 months of fundraising. The Madrid-based manager...

Goldman Sachs Alternatives has closed its ninth flagship buyout fund on $9.6bn, almost matching its $9.7bn predecessor despite the prolonged slowdown in global private capital fundraising.

Apollo has completed a €3bn investment in Bayer's long-acting reversible contraceptives business, with KKR joining the transaction as a significant minority participant. Apollo-managed funds...

Global private capital fundraising is heading for a fifth consecutive annual decline, with almost four-fifths of capital now flowing into funds of at least $1bn as liquidity-starved LPs concentrate commitments with larger managers, according to new PitchBook data.

Golub Capital has hired former Northleaf Capital Partners executive Matt Shafer to lead its GP-led private equity secondaries strategy, less than a year after committing more than $1bn to build the business.

Carlyle has raised about $2.3bn for its second infrastructure credit fund, taking in more than three-and-a-half times the capital secured for its predecessor as the investment giant scales its private infrastructure lending business.

Crane Venture Partners has raised $484m across four investment vehicles as the London-founded venture investor expands from its European roots into a globally connected early-stage investment platform spanning Europe, North America, India and Asia-Pacific.

Radical Ventures has secured more than $1bn at the first close of a new multi-billion-dollar late-stage AI fund, attracting commitments from some of Canada's largest pension investors as it looks to address a shortage of domestic growth capital for the country's technology businesses.

PSG Equity has closed its third European growth fund at more than €4.4bn, hitting its hard cap less than three years after collecting €2.6bn for its predecessor.

Frazier Life Sciences has raised more than $1.1bn from new and existing investors for its public biotechnology strategy, taking total commitments to the vehicle to approximately $2.8bn since its launch in 2021.